Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma

[Guest guest]

http://www3.interscience.wiley.com/journal/120848810/abstract

Liver International

Volume 29 Issue 2, Pages 203 - 207

Published Online: 25 Jul 2008

CLINICAL STUDIES

Efficacy of lamivudine on hepatitis B viral status and liver function in

patients with hepatitis B virus-related hepatocellular carcinoma

Ji Hoon Kim 1,2 , Joong-Won Park 1 , Dong Wook Koh 1 , Woo Jin Lee 1 and

Chang-Min Kim 1

1 Center for Liver Cancer, National Cancer Center, Goyang, Korea

2 Department of Internal Medicine, Korea University College of Medicine,

Seoul, Korea

Correspondence

Joong-Won Park, MD, PhD, Center for Liver Cancer, National Cancer Center, 809

Madu 1-dong, Ilsan-gu, Goyang, Gyeonggi 411-764, South Korea

Tel: +82 31 9201605

Fax: +82 31 9201520

e-mail: jwpark@...

ABSTRACT

Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC)

depends on the tumour extent and underlying liver function. Antiviral therapy

with nucleoside/nucleotide analogues has been shown to be effective in improving

the liver function of chronic hepatitis B (CHB) patients. We assessed whether

lamivudine could induce biochemical and virological improvements in patients

with hepatitis B virus-related HCC.

Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at

least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group).

Biochemical and virological parameters were serially monitored.

Results: Compared with the CHB group, the CHB/HCC group was older, had higher

male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin

and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg)

positivity (P

[Guest guest]

http://www3.interscience.wiley.com/journal/120848810/abstract

Liver International

Volume 29 Issue 2, Pages 203 - 207

Published Online: 25 Jul 2008

CLINICAL STUDIES

Efficacy of lamivudine on hepatitis B viral status and liver function in

patients with hepatitis B virus-related hepatocellular carcinoma

Ji Hoon Kim 1,2 , Joong-Won Park 1 , Dong Wook Koh 1 , Woo Jin Lee 1 and

Chang-Min Kim 1

1 Center for Liver Cancer, National Cancer Center, Goyang, Korea

2 Department of Internal Medicine, Korea University College of Medicine,

Seoul, Korea

Correspondence

Joong-Won Park, MD, PhD, Center for Liver Cancer, National Cancer Center, 809

Madu 1-dong, Ilsan-gu, Goyang, Gyeonggi 411-764, South Korea

Tel: +82 31 9201605

Fax: +82 31 9201520

e-mail: jwpark@...

ABSTRACT

Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC)

depends on the tumour extent and underlying liver function. Antiviral therapy

with nucleoside/nucleotide analogues has been shown to be effective in improving

the liver function of chronic hepatitis B (CHB) patients. We assessed whether

lamivudine could induce biochemical and virological improvements in patients

with hepatitis B virus-related HCC.

Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at

least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group).

Biochemical and virological parameters were serially monitored.

Results: Compared with the CHB group, the CHB/HCC group was older, had higher

male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin

and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg)

positivity (P